Kodiak Sciences Q2 net loss $45.1M, cash $219.2M; three Phase trials enrolling

Kodiak Sciences Inc.

2024-Q2 EPS reported -$1.68

Net loss $45.1M ($0.86/sh) vs $80.2M ($1.53/sh) in Q2 2023; R&D expense down 52% to $32.5M.
Cash and cash equivalents $219.2M; company believes funds operations into 2026.
Phase 3 GLOW2 (diabetic retinopathy) and DAYBREAK (wet AMD) actively enrolling; Phase 1b APEX (KSI-101) enrolling.
Appointed Dolly Chang (ex-Genentech) as CSO; promoted Almas Qudrat (CQO), Wayne To (CTO), Pablo Velazquez-Martin (CMO).
Investor Day scheduled for September 23, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.